OBJECTIVE: Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV. METHODS: We conducted a retrospective-matched case-control study of HIV-infected adult outpatients with and without thrombocytopenia to elucidate the contribution of HIV viremia, hepatitis C infection, and other potential risk factors for thrombocytopenia. Seventy-three cases with thrombocytopenia (platelet count <100 x 10(9)/L persistent for >3 months) were matched by age, sex, and first clinic visit with 73 nonthrombocytopenic controls. Risk factors and outcomes were assessed using conditional logistic regression. RESULTS: Nadir platelet counts in cases were <or=50 x 10(9)/L in 58% and <or=30 x 10(9)/L in 38%. In multivariate modeling, HIV RNA >400 copies/ml, hepatitis C virus infection, and cirrhosis were significantly associated with thrombocytopenia with adjusted odds ratios of 5.3 [confidence interval (CI) 1.6-17.1, P = 0.006], 6.1 (CI 1.6-22.6, P = 0.007), and 24.0 (CI 1.7-338, P = 0.019), respectively. Thrombocytopenia was significantly associated with major bleeding events and nonbleeding-related death. CONCLUSIONS: Thrombocytopenia in the era of potent antiretroviral therapy is associated with hepatitis C virus infection, cirrhosis, and uncontrolled HIV replication, and serious complications including major bleeding and death.
OBJECTIVE: Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV. METHODS: We conducted a retrospective-matched case-control study of HIV-infected adult outpatients with and without thrombocytopenia to elucidate the contribution of HIV viremia, hepatitis C infection, and other potential risk factors for thrombocytopenia. Seventy-three cases with thrombocytopenia (platelet count <100 x 10(9)/L persistent for >3 months) were matched by age, sex, and first clinic visit with 73 nonthrombocytopenic controls. Risk factors and outcomes were assessed using conditional logistic regression. RESULTS: Nadir platelet counts in cases were <or=50 x 10(9)/L in 58% and <or=30 x 10(9)/L in 38%. In multivariate modeling, HIV RNA >400 copies/ml, hepatitis C virus infection, and cirrhosis were significantly associated with thrombocytopenia with adjusted odds ratios of 5.3 [confidence interval (CI) 1.6-17.1, P = 0.006], 6.1 (CI 1.6-22.6, P = 0.007), and 24.0 (CI 1.7-338, P = 0.019), respectively. Thrombocytopenia was significantly associated with major bleeding events and nonbleeding-related death. CONCLUSIONS:Thrombocytopenia in the era of potent antiretroviral therapy is associated with hepatitis C virus infection, cirrhosis, and uncontrolled HIV replication, and serious complications including major bleeding and death.
Authors: Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George Journal: Blood Date: 2008-11-12 Impact factor: 22.113
Authors: J Servais; D Nkoghe; J C Schmit; V Arendt; I Robert; T Staub; M Moutschen; F Schneider; R Hemmer Journal: J Acquir Immune Defic Syndr Date: 2001-11-01 Impact factor: 3.731
Authors: S Carbonara; G Fiorentino; G Serio; P Maggi; G Ingravallo; L Monno; F Bruno; S Coppola; G Pastore; G Angarano Journal: J Infect Date: 2001-05 Impact factor: 6.072
Authors: L E Adinolfi; M G Giordano; A Andreana; M F Tripodi; R Utili; G Cesaro; E Ragone; E Durante Mangoni; G Ruggiero Journal: Br J Haematol Date: 2001-06 Impact factor: 6.998
Authors: Gunter Rieg; Michael Yeaman; Alice E Lail; Sharyne M Donfield; Edward D Gomperts; Eric S Daar Journal: AIDS Res Hum Retroviruses Date: 2007-10 Impact factor: 2.205
Authors: Mary B Wire; Heidi B McLean; Carolyn Pendry; Dickens Theodore; Jung W Park; Bin Peng Journal: Antimicrob Agents Chemother Date: 2012-03-05 Impact factor: 5.191
Authors: Sérgio M de Almeida; Clea E Ribeiro; Indianara Rotta; Scott Letendre; Michael Potter; Bin Tang; Meiri Batistela; Florin Vaida; Ronald J Ellis Journal: J Neurovirol Date: 2019-07-07 Impact factor: 2.643
Authors: Kelly A Metcalf Pate; Claire E Lyons; Jamie L Dorsey; Suzanne E Queen; Robert J Adams; Craig N Morrell; Joseph L Mankowski Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: Eva Zetterberg; Jacqueline Neuhaus; Jason V Baker; Charurut Somboonwit; Josep M Llibre; Adrian Palfreeman; Maria Chini; Jens D Lundgren Journal: AIDS Date: 2013-01-02 Impact factor: 4.177